Avadel Pharmaceuticals plc (AVDL)
USD 7.73
(0.65%)
USD 7.73
(0.65%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -160.27 Million USD | -16.59% |
| 2022 | -137.46 Million USD | -77.77% |
| 2021 | -77.32 Million USD | -1200.3% |
| 2020 | 7.02 Million USD | 121.15% |
| 2019 | -33.22 Million USD | 65.14% |
| 2018 | -95.3 Million USD | -241.71% |
| 2017 | 67.25 Million USD | 262.94% |
| 2016 | -41.27 Million USD | -201.52% |
| 2015 | 40.65 Million USD | 147.89% |
| 2014 | -84.9 Million USD | -97.8% |
| 2013 | -42.92 Million USD | -1229.77% |
| 2012 | -3.22 Million USD | 63.21% |
| 2011 | -8.77 Million USD | 2.24% |
| 2010 | -8.97 Million USD | 21.54% |
| 2009 | -11.43 Million USD | 5.34% |
| 2008 | -12.08 Million USD | 67.98% |
| 2007 | -37.73 Million USD | -7.2% |
| 2006 | -35.2 Million USD | -28.58% |
| 2005 | -27.37 Million USD | -319.03% |
| 2004 | 12.49 Million USD | 457.73% |
| 2003 | -3.49 Million USD | -216.27% |
| 2002 | 3 Million USD | 204.56% |
| 2001 | -2.87 Million USD | 69.62% |
| 2000 | -9.46 Million USD | -41.34% |
| 1999 | -6.69 Million USD | 14.31% |
| 1998 | -7.81 Million USD | -14.88% |
| 1997 | -6.8 Million USD | 1.45% |
| 1996 | -6.9 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -27.34 Million USD | 5.02% |
| 2024 Q2 | -13.82 Million USD | 49.45% |
| 2023 Q2 | -64.43 Million USD | -109.3% |
| 2023 Q1 | -30.78 Million USD | -12.15% |
| 2023 FY | -160.27 Million USD | -16.59% |
| 2023 Q3 | -36.27 Million USD | 43.7% |
| 2023 Q4 | -28.78 Million USD | 20.64% |
| 2022 Q4 | -27.45 Million USD | -36.26% |
| 2022 Q2 | -63.44 Million USD | -140.1% |
| 2022 FY | -137.46 Million USD | -77.77% |
| 2022 Q3 | -20.14 Million USD | 68.25% |
| 2022 Q1 | -26.42 Million USD | -18.49% |
| 2021 FY | -77.32 Million USD | -1200.3% |
| 2021 Q1 | -13.44 Million USD | -19.21% |
| 2021 Q2 | -19.58 Million USD | -45.64% |
| 2021 Q4 | -22.3 Million USD | -1.36% |
| 2021 Q3 | -22 Million USD | -12.36% |
| 2020 Q2 | 30.87 Million USD | 3669.25% |
| 2020 Q1 | -865 Thousand USD | 68.42% |
| 2020 Q3 | -11.7 Million USD | -137.91% |
| 2020 Q4 | -11.27 Million USD | 3.63% |
| 2020 FY | 7.02 Million USD | 121.15% |
| 2019 Q3 | -8.86 Million USD | -3.01% |
| 2019 Q4 | -2.73 Million USD | 69.1% |
| 2019 Q2 | -8.6 Million USD | 33.9% |
| 2019 Q1 | -13.01 Million USD | 79.61% |
| 2019 FY | -33.22 Million USD | 65.14% |
| 2018 Q1 | -12.23 Million USD | -32.11% |
| 2018 FY | -95.3 Million USD | -241.71% |
| 2018 Q2 | -3.43 Million USD | 71.9% |
| 2018 Q3 | -15.77 Million USD | -358.73% |
| 2018 Q4 | -63.85 Million USD | -304.91% |
| 2017 Q2 | 28.92 Million USD | 11.64% |
| 2017 Q1 | 25.91 Million USD | 447.32% |
| 2017 FY | 67.25 Million USD | 262.94% |
| 2017 Q4 | -9.26 Million USD | -142.72% |
| 2017 Q3 | 21.67 Million USD | -25.06% |
| 2016 Q3 | -22.29 Million USD | -11.72% |
| 2016 Q2 | -19.95 Million USD | -213.02% |
| 2016 Q1 | -6.37 Million USD | -108.38% |
| 2016 FY | -41.27 Million USD | -201.52% |
| 2016 Q4 | 4.73 Million USD | 121.23% |
| 2015 Q3 | -29.68 Million USD | -70.6% |
| 2015 Q4 | 76.09 Million USD | 356.35% |
| 2015 Q1 | 11.64 Million USD | 142.9% |
| 2015 Q2 | -17.4 Million USD | -249.39% |
| 2015 FY | 40.65 Million USD | 147.89% |
| 2014 Q1 | -26.63 Million USD | -619.56% |
| 2014 FY | -84.9 Million USD | -97.8% |
| 2014 Q4 | -27.14 Million USD | -170.25% |
| 2014 Q2 | -21.07 Million USD | 20.89% |
| 2014 Q3 | -10.04 Million USD | 52.33% |
| 2013 Q1 | -8.82 Million USD | -197.0% |
| 2013 FY | -42.92 Million USD | -1229.77% |
| 2013 Q3 | -6.36 Million USD | 80.61% |
| 2013 Q2 | -32.85 Million USD | -272.11% |
| 2013 Q4 | 5.12 Million USD | 180.5% |
| 2012 FY | -3.22 Million USD | 63.21% |
| 2012 Q4 | 9.1 Million USD | 241.67% |
| 2012 Q1 | 12 Thousand USD | 100.57% |
| 2012 Q2 | -1.31 Million USD | -11066.67% |
| 2012 Q3 | -6.42 Million USD | -388.22% |
| 2011 Q3 | 1.7 Million USD | 149.23% |
| 2011 FY | -8.77 Million USD | 2.24% |
| 2011 Q4 | -2.09 Million USD | -222.78% |
| 2011 Q1 | -4.92 Million USD | -283.98% |
| 2011 Q2 | -3.45 Million USD | 29.8% |
| 2010 Q2 | -4.29 Million USD | 20.59% |
| 2010 FY | -8.97 Million USD | 21.54% |
| 2010 Q4 | 2.67 Million USD | 158.85% |
| 2010 Q1 | -5.4 Million USD | 5.18% |
| 2010 Q3 | -4.55 Million USD | -6.07% |
| 2009 Q3 | -3.38 Million USD | 4.73% |
| 2009 FY | -11.43 Million USD | 5.34% |
| 2009 Q4 | -5.69 Million USD | -68.45% |
| 2009 Q1 | 1.19 Million USD | 143.65% |
| 2009 Q2 | -3.55 Million USD | -398.32% |
| 2008 Q1 | -3.69 Million USD | 37.75% |
| 2008 Q4 | -2.72 Million USD | -18.32% |
| 2008 Q3 | -2.3 Million USD | 31.39% |
| 2008 FY | -12.08 Million USD | 67.98% |
| 2008 Q2 | -3.35 Million USD | 9.15% |
| 2007 Q4 | -5.93 Million USD | 34.8% |
| 2007 Q3 | -9.1 Million USD | 33.21% |
| 2007 Q2 | -13.63 Million USD | -50.46% |
| 2007 Q1 | -9.06 Million USD | -54.7% |
| 2007 FY | -37.73 Million USD | -7.2% |
| 2006 FY | -35.2 Million USD | -28.58% |
| 2006 Q4 | -5.85 Million USD | 42.66% |
| 2006 Q3 | -10.21 Million USD | -7.89% |
| 2006 Q2 | -9.46 Million USD | 2.0% |
| 2006 Q1 | -9.66 Million USD | -49.83% |
| 2005 Q2 | -9.23 Million USD | -5089.19% |
| 2005 Q3 | -11.88 Million USD | -28.75% |
| 2005 FY | -27.37 Million USD | -319.03% |
| 2005 Q1 | 185 Thousand USD | -98.1% |
| 2005 Q4 | -6.44 Million USD | 45.74% |
| 2004 Q1 | 4.29 Million USD | 153.06% |
| 2004 Q2 | -1.55 Million USD | -136.19% |
| 2004 Q4 | 9.75 Million USD | 727.46% |
| 2004 Q3 | -1.55 Million USD | 0.0% |
| 2004 FY | 12.49 Million USD | 457.73% |
| 2003 Q2 | -1.65 Million USD | 1.37% |
| 2003 Q1 | -1.67 Million USD | -411.62% |
| 2003 Q4 | 1.69 Million USD | 190.85% |
| 2003 FY | -3.49 Million USD | -216.27% |
| 2003 Q3 | -1.86 Million USD | -13.27% |
| 2002 FY | 3 Million USD | 204.56% |
| 2002 Q1 | -79 Thousand USD | 0.0% |
| 2002 Q2 | -1.65 Million USD | -1988.61% |
| 2002 Q3 | 2.37 Million USD | 243.82% |
| 2002 Q4 | -327 Thousand USD | -113.78% |
| 2001 Q2 | -1.36 Million USD | -76.85% |
| 2001 Q4 | -79 Thousand USD | 88.14% |
| 2001 FY | -2.87 Million USD | 69.62% |
| 2001 Q3 | -666 Thousand USD | 51.03% |
| 2001 Q1 | -769 Thousand USD | -121.73% |
| 2000 Q4 | 3.53 Million USD | 453.9% |
| 2000 Q2 | -990 Thousand USD | 84.4% |
| 2000 Q1 | -6.34 Million USD | -390.39% |
| 2000 FY | -9.46 Million USD | -41.34% |
| 2000 Q3 | -1 Million USD | -1.01% |
| 1999 FY | -6.69 Million USD | 14.31% |
| 1999 Q4 | 2.18 Million USD | 173.7% |
| 1999 Q3 | -2.96 Million USD | 2.34% |
| 1999 Q2 | -3.03 Million USD | -4.72% |
| 1999 Q1 | -2.9 Million USD | -79.9% |
| 1998 Q2 | -1.6 Million USD | 33.33% |
| 1998 Q3 | -2.2 Million USD | -37.5% |
| 1998 FY | -7.81 Million USD | -14.88% |
| 1998 Q4 | -1.61 Million USD | 26.73% |
| 1998 Q1 | -2.4 Million USD | -2500.0% |
| 1997 Q4 | 100 Thousand USD | 103.45% |
| 1997 FY | -6.8 Million USD | 1.45% |
| 1997 Q1 | -1.7 Million USD | -6.25% |
| 1997 Q2 | -2.2 Million USD | -29.41% |
| 1997 Q3 | -2.9 Million USD | -31.82% |
| 1996 Q2 | -2.4 Million USD | -60.0% |
| 1996 Q1 | -1.5 Million USD | 0.0% |
| 1996 Q3 | -1.4 Million USD | 41.67% |
| 1996 Q4 | -1.6 Million USD | -14.29% |
| 1996 FY | -6.9 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 432.834% |
| Embecta Corp. | 70.4 Million USD | 327.665% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 953.485% |
| Dynavax Technologies Corporation | -6.38 Million USD | -2408.624% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 23.404% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 482.019% |
| PainReform Ltd. | -9.34 Million USD | -1615.283% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -1936.544% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -3456.912% |
| SCYNEXIS, Inc. | 67.04 Million USD | 339.072% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -5072.643% |
| Cosmos Health Inc. | -18.54 Million USD | -764.364% |
| Journey Medical Corporation | -3.85 Million USD | -4059.772% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -3456.912% |
| Safety Shot Inc | -15.08 Million USD | -962.624% |
| Alpha Teknova, Inc. | -36.78 Million USD | -335.769% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | -14.75% |
| Bright Green Corporation | -13.12 Million USD | -1120.904% |
| Procaps Group, S.A. | 42.54 Million USD | 476.765% |
| Theratechnologies Inc. | -23.95 Million USD | -569.015% |
| Harrow Health, Inc. | -24.41 Million USD | -556.573% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -3214.912% |
| Biofrontera Inc. | -20.13 Million USD | -696.165% |
| DURECT Corporation | -27.62 Million USD | -480.206% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 12279.027% |
| Cronos Group Inc. | -73.96 Million USD | -116.698% |
| OptiNose, Inc. | -35.48 Million USD | -351.698% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 84.008% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -279.81% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 770.162% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 3341.173% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 101519.324% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -2452.442% |
| Radius Health, Inc. | -25.79 Million USD | -521.442% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -2500.591% |
| ProPhase Labs, Inc. | -16.78 Million USD | -855.047% |
| Phibro Animal Health Corporation | 2.41 Million USD | 6733.94% |
| Procaps Group S.A. | 42.54 Million USD | 476.765% |
| Alvotech | -551.73 Million USD | 70.95% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -1459.408% |
| Viatris Inc. | 54.7 Million USD | 393.009% |
| Rockwell Medical, Inc. | -8.43 Million USD | -1799.23% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -911.588% |
| SIGA Technologies, Inc. | 68.06 Million USD | 335.462% |
| Tilray Brands, Inc. | -244.98 Million USD | 34.576% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 1434.188% |
| Shineco, Inc. | -22.44 Million USD | -613.956% |
| PetIQ, Inc. | 2.13 Million USD | 7621.164% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -3625.757% |
| Incannex Healthcare Limited | -18.45 Million USD | -768.281% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 164.187% |
| Alimera Sciences, Inc. | -20.13 Million USD | -696.126% |
| Silver Spike Investment Corp. | 7.34 Million USD | 2283.565% |
| Assertio Holdings, Inc. | -331.94 Million USD | 51.716% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -2331.105% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -1863.4% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | -795.447% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -699.091% |
| Hempacco Co., Inc. | -13.12 Million USD | -1121.05% |
| Talphera, Inc. | -18.39 Million USD | -771.207% |
| Alvotech | -551.73 Million USD | 70.95% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 549.683% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 149.065% |
| Currenc Group, Inc. | -15.3 Million USD | -947.107% |
| Kamada Ltd. | 8.28 Million USD | 2034.766% |
| Indivior PLC | 2 Million USD | 8113.8% |
| Evoke Pharma, Inc. | -7.79 Million USD | -1956.852% |
| Flora Growth Corp. | -57.03 Million USD | -181.008% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -699.091% |
| Evolus, Inc. | -61.68 Million USD | -159.83% |
| HUTCHMED (China) Limited | 100.78 Million USD | 259.036% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 216.526% |
| Akanda Corp. | -32.27 Million USD | -396.594% |